马兜铃酸

mǎ dōu línɡ suān
  • aristolochic acid
马兜铃酸马兜铃酸
  1. 目的观察联合应用前列腺素E1(PGE1,凯时)和羟苯磺酸钙(安多明)对马兜铃酸肾病(AAN)的临床疗效。

    Objective To study the effects of integrated liposomal prostaglandin E_1 ( PGE_1 ) and calcium dobesilate on aristolochic acid nephropathy ( AAN ) .

  2. 目的探讨血小板反应因子1(TSP-1)与慢性马兜铃酸肾病(CAAN)肾间质纤维化及肾小管周围毛细血管(PTC)丢失的关系。

    Objective To investigate the relationship of up-regulated thrombospondin 1 ( TSP-1 ) expression with renal interstitial fibrosis and peritubular capillary loss in chronic aristolochic acid nephropathy ( CAAN ) .

  3. 反相HPLC法测定青木香药材中马兜铃酸A的含量

    Determination of Aristolochic Acid A in Drugs from Aristolochia by RP-HPLC

  4. 马兜铃酸Ⅰ致肾小管上皮细胞DNA损伤的逆转性实验

    The reverse of DNA damage and cell cycle arrestment induced by aristolochic acid ⅰ in renal tubule epithelial cells

  5. 目的研究马兜铃酸(AA)体外致DNA损伤作用。

    Objective To study the DNA damage induced by aristolochic acid ( AA ) in vitro .

  6. HPLC法测定导赤散及其配伍组中马兜铃酸A含量的实验研究

    The Study of Experiments on Detemination of Aristolochic Acid A in Daochi San and Compatibility Groups by HPLC

  7. 结论华细辛中马兜铃酸A含量在6.8~45.4μg·g~(-1)。

    CONCLUSION The concentration of aristolochic acid A is between 6.8 and 45.4 μ g · g ~ ( - 1 ) .

  8. 马兜铃酸所致肾损伤机制涉及DNA损害、肾小管细胞转分化等。马兜铃酸与DNA形成加合物可能是其肾毒性和致癌性的重要机制。

    Aristolochic acid ( AA ) damages DNA and forms DNA adducts , which may be one of the important mechanisms causing its nephrotoxicity and carcinogenesis .

  9. RP-HPLC法测定不同方法炮制关木通中马兜铃酸A的含量

    RP-HPLC Determination of Content of Aristolochic Acid A in Different processing with Manchurian Dutchmanspipe Stem

  10. 伴有慢性肾衰竭的马兜铃酸肾病与IgA肾病的配对研究

    Matched Case-Controlled Study of Aristolochic Acid Nephropathy and IgA Nephropathy in Patients with Chronic Renal Failure

  11. 目的:目前国内外尚未见有马兜铃酸(AA)诱导实验动物慢性肾间质纤维化的报告。

    Objective : It has not been reported that the aristolochic acid ( AA ) may induce chronic renal interstitial fibrosis in rats .

  12. 因此,国外学者将此病称为中草药肾病(CHN),该命名显然不妥,国内学者建议称为马兜铃酸肾病(AAN)。

    Therefore they named the disease Chinese herbs nephropathy ( CHN ), which is obviously inappropriate .

  13. 在大量病因学研究基础上,我国学者提出中草药肾病的命名欠妥,应称之为马兜铃酸肾病(aristolochicacidnephropathy,AAN)。

    Based on a great deal of etiological research , scholars in our country alleged it should be named by " Aristolochic Acid Nephropathy "( AAN ) rather than CHN .

  14. 结论80和160μg/mlAA对HK-2有明显细胞毒作用,此作用可能与急性马兜铃酸肾病发病相关;

    Conclusions The cytotoxic effects of AA in the concentrations of 80 and 160 μ g / ml on HK-2 may be related to pathogenesis of acute AA nephropathy .

  15. 目的:探讨百令胶囊加泼尼松治疗慢性马兜铃酸肾病(AAN)的疗效。

    Objective : To investigate the efficacy of corbrin capsule plus prednisone therapy for chronic aristolochic acid nephropathy ( AAN ) .

  16. 本实验所使用的关木通其药材中的总马兜铃酸含量为15.0mg/g,制各的关木通水煎剂(3g生药/ml)其总马兜铃酸含量为4.5mg/ml。

    The total aristolochic acid contents of CAM was 15.0mg / g , and total aristolochic acid contents of its decoction was 4.5mg/ml .

  17. 慢性马兜铃酸肾病TSP-1高表达与肾间质纤维化及微血管丢失的关系

    The Relationships between the Higher Expression of TSP-1 and Renal Interstitial Fibrosis as well as Peritubular Capillary Loss in Chronic Aristolochic Acid Nephropathy

  18. 结果:112例TCC患者中有18例(16.1%)曾服用含AA成分药物,其中2例诊断马兜铃酸肾病。

    Results : Eighteen ( 16.1 % ) of the 112 patients had a history of taking AA-containing Chinese medicine , and 2 of them were diagnosed as aristolochic acid nephropathy ( AAN ) .

  19. 选取短刺小克银汉霉菌(CunninghamellablakesleanaAS3.910)用微生物转化的方法对马兜铃酸A(AristolochicAcid)进行了代谢转化研究并比较了微生物转化产物和哺乳动物体内的代谢产物的异同。

    To study aristolochic acid I transformation by Cunninghamella Blakesleana ( AS3.910 ) and to make a contrast between transformation metabolites and mammalian metabolites .

  20. 目的探讨慢性马兜铃酸肾病(CAAN)大鼠模型的早期贫血机制。

    Objective To investigate the mechanism of early anemia in rat model of chronic aristolochic acid nephropathy ( CAAN ) .

  21. 目的:探讨尿路移行细胞癌(Transitionalcellcarcinoma,TCC)患者服用含马兜铃酸(AristolochicAcid,AA)成分药物的情况和与AA相关TCC的临床特点。

    Objective : To probe the status of patients with urinary transitional cell carcinoma who have ever taken the medicine containing aristolochic acid ( AA ), and the clinical characteristics of urinary transitional cell carcinoma ( TCC ) associated with AA .

  22. 通过对不同肾功能阶段的含马兜铃酸中药肾损害临床患者进行观察,发现随着肾损害的进一步发展,尿RBP和β2-M呈现进行性升高。

    Analysis of different stage of renal damage induced by AA-containing herbs showed that urine RBP and β _2-M raised with the development of renal damage .

  23. 摘要:目的探讨马兜铃酸是否能进入人近端肾小管上皮细胞(HKC)及其进入HKC的可能途径。

    ABSTRACT : Objective To investigate whether aristolochic acid can be transported into human kidney proximal tubular cell ( HKC ) and its potential mechanism .

  24. 利用CD和FTIR技术考察了马兜铃酸对牛血清白蛋白二级结构的影响,CD结果表明马兜铃酸与BSA的键合使BSA中α-螺旋结构含量从43.5%降到36.7%。

    In addition , the effects of aristolochic acid on the protein second structure were studied using CD and FTIR techniques . The results of CD proved that the α - helix contents of BSA decreased from 43.5 % to 36.7 % after binding with aristolochic acid .

  25. 目的研究中药方剂益肾软坚散能否对慢性马兜铃酸肾病(CAAN)大鼠的肾损害起到保护作用。

    ObjectiveTo study the protective effects of Yishen Ruanjian Power ( YRP ) on renal interstitial fibrosis in rats with chronic aristolochic acid induced nephropathy ( CAAN ) .

  26. 观察补肾活血法治疗马兜铃酸肾病(AAN)的临床疗效。将65例马兜铃酸肾病患者,采用补肾活血法为主辨证治疗,疗程8周。

    To observe the clinical efficacy of kidney nourishing and blood activating therapy in the treatment of aristolochic acid nephropathy ( AAN ), 65 cases were treated by this therapy for 8 weeks .

  27. 目的:研究慢性马兜铃酸肾病(CAAN)大鼠肾小管上皮细胞-肌成纤维细胞转分化(TEMT)与肾间质纤维化之间关系。

    Objective : To investigate the relationship between renal tubular epithelial-myofibroblast transdifferentiation ( TEMT ) and renal interstitial fibrosis in the rats with chronic aristolochic acid nephropathy ( CAAN ) .

  28. 目的探讨单个核细胞趋化蛋白1(MCP1)和马兜铃酸Ⅰ(AristolochicAcidⅠ,AAⅠ)及其两者的协同作用,对人类肾小管上皮细胞(HKC)转分化的影响。

    Objective To test the possible role of monocyte chemotactic protein-1 ( MCP-1 ) and its synergistic effect with aristolochic acid I ( AA ⅰ) on tubular epithelial-myofibroblast transdifferentiation ( TEMT ) of human renal tubular epithelial cells ( HKC ) in vitro .

  29. 目的:从毒代动力学的角度探讨马兜铃酸-I(AA-I)的肾毒性机制。

    Objective : To study the mechanism of nephrotoxicity from aristolochic acid - I ( AA - I ) in terms of toxicokinetics .

  30. 目的探讨马兜铃酸(AA)对体外培养的人肾小管上皮细胞株(HK-2)及人肾间质成纤维细胞(hRIFs)的作用。

    Objective To investigate the effects of aristolochic acid ( AA ) on cell proliferation , cytotoxicity and mRNA expression of some cytokines in cultured human renal interstitial fibroblasts ( hRIFs ) and human renal tubular epithelial cell line ( HK-2 ) .